# A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors

> **NCT05810103** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- HER2-positive Advanced Solid Tumors

## Interventions

- **DRUG:** DP303c

## Key facts

- **NCT ID:** NCT05810103
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-06
- **Primary completion:** 2023-12-23
- **Final completion:** 2024-03-23
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2023-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810103, "A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05810103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*